Plain-English translation of NCT06532084 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a targeted cancer drug, to see if it can help prevent blood cancers from returning after patients receive a stem cell transplant. Patients with high-risk blood cancers (like advanced leukemia or certain forms of bone marrow disease) are at greater risk of their cancer coming back even after a successful transplant. The medication is given for about 5.5 months starting around day 100 after the transplant, and researchers want to know if this treatment can keep cancer away longer than usual care alone.
Even with modern stem cell transplants, patients with aggressive or hard-to-treat blood cancers still face a high risk of relapse. Although a newer transplant approach called PTBCy improves disease control early on, this benefit fades over time, and cancer often returns within months. This trial exists to find out whether adding this medication during a critical window after transplant can extend the time patients stay cancer-free.
You likely qualify if…
You likely don't qualify if…
If you qualify and are randomly selected, you will either receive (200 mg twice daily for about 5.5 months, starting around day 100 after your transplant) or continue with standard follow-up care. Throughout the study, you will have regular blood tests and clinic visits to monitor your health, check for any side effects, and watch for signs of cancer relapse. The trial will follow you to see whether the medication helps keep your cancer from returning compared to usual care.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Russia